Prime’s clinical researchers presented four award-winning research
studies at AMCP Nexus. Explore their findings, and learn about
potential health and cost impacts. Study 1: Cumulative
Health care spend among U.S. seniors is wildly disproportionate. At
13 percent, those ages 65 and older make up a small segment of the
population. Yet they account for more than one-third of all health
care costs — spending at a rate three times that...
PSCK9 inhibitors have been dominating the headlines. And for good
reason. With annual, per-patient costs topping $14,000 — as much as
50 times the cost of highly effective, yet highly underutilized
statins — they pose a substantial threat to health...
The cancer progression-pausing power is extraordinary. So are the
risks and the costs. The U.S. Food and Drug Administration (FDA)
approved Ibrance in February 2015 to treat a certain type of breast
cancer in postmenopausal women. And uptake has...